- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白實(shí)驗(yàn)
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag親和凝膠
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 細(xì)胞核與細(xì)胞漿蛋白抽提試劑盒
- 免疫磁珠
- 蛋白酶抑制劑Cocktail
- 蛋白酶抑制劑Cocktail(DMSO儲液)
- 磷酸酶抑制劑Cocktail
- 細(xì)胞實(shí)驗(yàn)
- Cell Counting Kit-8 (CCK-8)
- 新產(chǎn)品
- 聯(lián)系我們
Cycloheximide
別名: NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80 中文名稱：放線菌酮，環(huán)己酰亞胺
此產(chǎn)品請避光密封保存。
Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一種抗真菌抗生素，是一種真核生物蛋白質(zhì)合成（protein synthesis）抑制劑，對體內(nèi)蛋白質(zhì)合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分別為 532.5 nM 和 2880 nM。Cycloheximide抑制鐵死亡并抑制自噬。Cycloheximide?(NSC-185) 可用于誘導(dǎo)記憶障礙動物模型。在溶液中不穩(wěn)定，請現(xiàn)配現(xiàn)用！此產(chǎn)品為危化品（急性毒性/易燃/皮膚腐蝕），請?jiān)诖┐鞣雷o(hù)面罩、防護(hù)手套和防護(hù)服后使用。 已取得危險(xiǎn)化學(xué)品經(jīng)營許可
Cycloheximide Chemical Structure
CAS: 66-81-9
產(chǎn)品質(zhì)控
批次：
S741805
DMSO]56 mg/mL]false]Ethanol]56 mg/mL]false]Water]15 mg/mL]false
純度：
99%
99
Cycloheximide相關(guān)產(chǎn)品
| 相關(guān)產(chǎn)品 | Tolnaftate Amorolfine HCl Neticonazole Pseudolaric Acid B Climbazole Bifonazole Butylparaben Isavuconazole Thimerosal Neticonazole Hydrochloride Juglone | 點(diǎn)擊展開 |
|---|---|---|
| 相關(guān)化合物庫 | 激酶抑制劑庫 FDA藥物庫 天然產(chǎn)物庫 已知活性藥物庫-I 高選擇性抑制劑庫 | 點(diǎn)擊展開 |
細(xì)胞實(shí)驗(yàn)數(shù)據(jù)示例
| 細(xì)胞系 | 實(shí)驗(yàn)類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻(xiàn)信息(PMID) |
|---|---|---|---|---|---|
| MCF7 | Function assay | 10 ug/mL | 1 hr | Inhibition of HIF1alpha RNA translation in human MCF7 cells at 10 ug/mL pretreated for 1 hr prior to metabolic labeling by SDS-PAGE analysis | 22607231 |
| AGS | Apoptosis assay | 150 ug/mL | 48 hrs | Induction of apoptosis in human AGS cells assessed as early apoptosis level at 150 ug/mL after 48 hrs by Annexin V-FITC apoptosis assay | 21899268 |
| T47D | Function assay | 10 uM | 4 hrs | Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 0.3 uM | 4 hrs | Inhibition of 1,10-phenanthroline-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 3 uM | 16 hrs | Inhibition of hypoxia-induced HIF1 activation in human T47D cells at 3 uM after 16 hrs by luciferase reporter gene assay | 15974627 |
| T47D | Function assay | 0.7 uM | 16 hrs | Inhibition of 1,10-phenanthroline-induced HIF1 activation in human T47D cells at 0.7 uM after 16 hrs by luciferase reporter gene assay | 15974627 |
| T47D | Function assay | 10 uM | 16 hrs | Inhibition of hypoxia-induced VEGF expression in human T47D cells at 10 uM after 16 hrs by ELISA | 15974627 |
| T47D | Function assay | 0.3 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 0.3 uM after 4 hrs by Western blotting | 15974627 |
| T47D | Function assay | 10 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha activation in human T47D cells at 10 uM after 4 hrs by Western blotting | 15974627 |
| HEK293T | Function assay | 50 uM | 30 mins | Effect on polyribosome profiling in human HEK293T cells assessed as depletion of polysomes at 50 uM after 30 mins by spectrophotometry | 20118940 |
| T47D | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human T47D cells at 10 uM after 48 hrs by SRB assay | 23434131 |
| MDA-MB-231 | Antiproliferative assay | 10 uM | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells at 10 uM after 48 hrs by SRB assay | 23434131 |
| NCI-H460 | Function assay | 10 ug/mL | up to 9 hrs | Reduction of HSP1 stability in human NCI-H460 cells assessed as protein degradation at 10 ug/mL up to 9 hrs by Western blot analysis | 24746225 |
| HeLa | Cytotoxicity assay | 25 uM | 18 hrs | Cytotoxicity against human HeLa cells assessed as reduction in cell viability at 25 uM after 18 hrs by inverse MTT assay | 25028062 |
| RAW264.7 | Function assay | 70 uM | 6 hrs | Inhibition of luminescence emission in mouse RAW264.7 cells transfected with luciferase plasmid containing universal promoter PKG at 70 uM after 6 hrs by luciferase reporter gene assay | 25667960 |
| HepG2-A16-CD81 | Function assay | 10 uM | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration, IC50 = 0.0781 μM. | 22096101 | |
| neural precursor cells | Function assay | 3 uM | Induction of neurosphere phenotype changes in mouse neural precursor cells at 3 uM | 17417631 | |
| Jurkat T-cells | Function assay | 48 hours | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC50 = 0.93 μM. | 11052798 | |
| Jurkat T-cells | Function assay | 48 hours | Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours, IC80 = 1.54 μM. | 11052798 | |
| HeLa | Cytotoxicity assay | 24 hrs | Cytotoxicity against human HeLa cells after 24 hrs, CD50 = 0.1 μM. | 18394884 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.912 μM. | 18771242 | |
| HeLa | Function assay | 2 hrs | Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy, IC50 = 0.5325 μM. | 20118940 | |
| HeLa | Function assay | 2 hrs | Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting, IC50 = 2.8801 μM. | 20118940 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. | 20356064 | |
| BESM | Function assay | 88 hrs | Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay, EC50 = 0.4 μM. | 20547819 | |
| NIH/3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay, IC50 = 1.1 μM. | 21899268 | |
| MDA-MB-231 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 1.2 μM. | 21899268 | |
| AGS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human AGS cells after 48 hrs by MTT assay, IC50 = 3.6 μM. | 21899268 | |
| HT-29 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay, IC50 = 12.8 μM. | 21899268 | |
| 3T3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay, IC50 = 0.26 μM. | 22437110 | |
| PA1 | Cytotoxicity assay | 24 hrs | Cytotoxicity against human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. | 23202484 | |
| PA1 | Growth inhibition assay | 24 hrs | Growth inhibition of human PA1 cells after 24 hrs by MTT assay, IC50 = 40.6 μM. | 28011220 | |
| CEM | Cytotoxicity assay | 5 days | Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay, IC50 = 0.2 μM. | 29778528 | |
| Vero | Cytotoxicity assay | 3 days | Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay, IC50 = 0.2 μM. | 29778528 | |
| 3T3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against rat 3T3 cells after 48 hrs by MTT assay, IC50 = 0.61 μM. | 30146096 | |
| CEM | Anticancer assay | Tested in vitro for anticancer activity against CEM cells, IC50 = 0.12 μM. | 10072683 | ||
| 9L | Anticancer assay | Tested in vitro for anticancer activity against 9L cells, IC50 = 0.2 μM. | 10072683 | ||
| SK-MEL-28 | Anticancer assay | Tested in vitro for anticancer activity against SK-MEL-28 cells, IC50 = 1 μM. | 10072683 | ||
| Vero | Cytotoxicity assay | Tested in vitro for cytotoxicity against Vero cells, IC50 = 1.2 μM. | 10072683 | ||
| LNCaP | Anticancer assay | Tested in vitro for anticancer activity against LNCaP cells, IC50 = 1.2 μM. | 10072683 | ||
| MCF-7 | Anticancer assay | Tested in vitro for anticancer activity against MCF-7 cells, IC50 = 1.5 μM. | 10072683 | ||
| PBM | Cytotoxicity assay | Tested in vitro for cytotoxicity against PBM cells, IC50 = 2.1 μM. | 10072683 | ||
| HepG2 | Anticancer assay | Tested in vitro for anticancer activity against HepG2 cells, IC50 = 2.5 μM. | 10072683 | ||
| SK-MES-1 | Anticancer assay | Tested in vitro for anticancer activity against SK-MES-1 cells, IC50 = 2.7 μM. | 10072683 | ||
| PC-3 | Anticancer assay | Tested in vitro for anticancer activity against PC-3 cells, IC50 = 3.5 μM. | 10072683 | ||
| Jurkat T-cells | Function assay | Inhibitory concentration against Human Jurkat T cells, IC50 = 0.93 μM. | 10212121 | ||
| Jurkat T-cells | Function assay | Inhibitory concentration against Human Jurkat T cells, IC80 = 1.54 μM. | 10212121 | ||
| CEM | Cytotoxicity assay | Cytotoxicity was determined in CEM cells, relative to RVT, IC50 = 0.08 μM. | 15081000 | ||
| PBM | Cytotoxicity assay | Cytotoxicity was determined in PBM cells, relative to RVT, IC50 = 0.46 μM. | 15081000 | ||
| Vero | Cytotoxicity assay | Cytotoxicity was determined in Vero cells, relative to RVT, IC50 = 0.53 μM. | 15081000 | ||
| HeLa | Function assay | Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay, IC50 = 0.036 μM. | 15974627 | ||
| medulloblastoma cells | Antiproliferative assay | Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay, EC50 = 0.042 μM. | 17417631 | ||
| neural precursor cells | Antiproliferative assay | Antiproliferative activity against mouse neural precursor cells by colony formation assay, EC50 = 0.054 μM. | 17417631 | ||
| astrocyte cells | Antiproliferative assay | Antiproliferative activity against mouse astrocyte cells by MTT assay, EC50 = 0.071 μM. | 17417631 | ||
| neural precursor cells | Antiproliferative assay | Antiproliferative activity against mouse neural precursor cells by MTT assay, EC50 = 0.142 μM. | 17417631 | ||
| HepG2 | Function assay | HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells, IC50 = 0.047 μM. | 22586124 | ||
| 3T3 | Cytotoxicity assay | Cytotoxicity against mouse 3T3 cells by SRB assay, IC50 = 0.3 μM. | 29247859 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells | 29435139 | ||
| HeLa | Cytotoxicity assay | Cytotoxicity against human HeLa cells assessed as inhibition of DNA replication by imaging analysis | 18066055 | ||
| HeLa | Function assay | Inhibition of mitosis in human HeLa cells by imaging analysis | 18066055 | ||
| 點(diǎn)擊查看更多細(xì)胞系數(shù)據(jù) | |||||
生物活性
| 產(chǎn)品描述 | Cycloheximide (NSC-185, Actidione, Naramycin A, CHX, FT 3422-2, NM-MCD 80)，一種抗真菌抗生素，是一種真核生物蛋白質(zhì)合成（protein synthesis）抑制劑，對體內(nèi)蛋白質(zhì)合（protein synthesis）和 RNA 合成（RNA synthesis）的 IC50 分別為 532.5 nM 和 2880 nM。Cycloheximide抑制鐵死亡并抑制自噬。Cycloheximide?(NSC-185) 可用于誘導(dǎo)記憶障礙動物模型。在溶液中不穩(wěn)定，請現(xiàn)配現(xiàn)用！此產(chǎn)品為危化品（急性毒性/易燃/皮膚腐蝕），請?jiān)诖┐鞣雷o(hù)面罩、防護(hù)手套和防護(hù)服后使用。 |
|---|
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03700788 | Not yet recruiting | Apical Periodontitis |
University of Southern California |
May 30 2023 | Phase 3 |
| NCT05506566 | Recruiting | Tumor|Positron-Emission Tomography |
First Affiliated Hospital of Fujian Medical University |
May 1 2022 | Phase 1|Phase 2 |
| NCT02202304 | Withdrawn | Periodontal Disease|Caries |
Rosa Moreno Lopez|Ivoclar Vivadent AG|University of Aberdeen |
September 10 2017 | Phase 4 |
| NCT01521325 | Completed | Mesothelioma|Pancreatic Cancer|Ovarian Cancer|Non-small Cell Lung Cancer |
Morphotek |
September 2011 | Phase 1 |
| NCT02168374 | Completed | Dental Caries |
Aline R F de Castilho|Funda??o de Amparo à Pesquisa do Estado de S?o Paulo|University of Campinas Brazil |
March 2008 | Phase 2 |
|
化學(xué)信息&溶解度
| 分子量 | 281.35 | 分子式 | C15H23NO4 |
| CAS號 | 66-81-9 | SDF | -- |
| Smiles | CC1CC(C(=O)C(C1)C(CC2CC(=O)NC(=O)C2)O)C | ||
| 儲存條件(自收到貨起) | 3年 -20°C(避光) 粉狀 |
||
|
體外溶解度 |
DMSO : 56 mg/mL ( (199.04 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Ethanol : 56 mg/mL (199.04 mM) Water : 15 mg/mL (53.31 mM) |
摩爾濃度計(jì)算器 |
|
體內(nèi)溶解配方 現(xiàn)配現(xiàn)用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內(nèi)配方計(jì)算器 | |||||
實(shí)驗(yàn)計(jì)算
摩爾濃度計(jì)算器
動物體內(nèi)配方計(jì)算器（澄清溶液）
第一步：請輸入基本實(shí)驗(yàn)信息（考慮到實(shí)驗(yàn)過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內(nèi)配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計(jì)算結(jié)果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內(nèi)配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內(nèi)配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進(jìn)行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術(shù)支持
在訂購、運(yùn)輸、儲存和使用我們的產(chǎn)品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術(shù)支持郵箱[email protected]，直接聯(lián)系到我們。我們會在24小時內(nèi)盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項(xiàng)
